Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.

Interleukin 10 (IL-10)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Inflammation
Use
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

IL-10 cytokine which can act as a marker from inflammation. High levels of IL-10 were significantly associated with amyloid deposition in healthy controls, suggesting that these two biomarkers might be used to detect at risk individuals.

Length of Current Trial
18 and 54 months
Number of Trial Participants

665

What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

School of Medical Sciences, Edith Cowan University, Joondalup, WA 6027, Australia;Co-operative Research Centre for Mental Health, Carlton, VIC 3053, Australia;CSIRO Digital Productivity Flagship, Brisbane, QLD 4029, Australia;University of North Texas Health Science Center, Fort Worth, 76107, Texas, USA; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA 6150, Australia; The Florey Institute, The University of Melbourne, Parkville, VIC 3052, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia; National Ageing Research Institute, Parkville, VIC 3052, Australia; Academic Unit for Psychiatry of Old age, St. George’s Hospital, The University of Melbourne, Parkville, VIC 3052, Australia; School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, WA 6009, Australia; Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia; Department of Psychology, Macquarie University, Sydney, NSW 2109, Australia; CSIRO; The University of Melbourne, Parkville, VIC 3052, Australia; Cogstate Ltd., Melbourne, VIC 3000, Australia; Alzheimer Australia Vic, Hawthorne, VIC 3122, Australia; St. Vincent Hospital, Fitzroy, VIC 3065, Australia; University of Western Australia, Crawley, WA 6009, Australia; School of Biomedical Sciences, Curtin University, Bentley, WA 6102, Australia

  1. “IL10 interleukin 10 [ Homo sapiens (human) ].” Gene ID;NCBI. https://www.ncbi.nlm.nih.gov/gene/3586

  2. Pedrini, S., Gupta, V. B., Hone, E., Doecke, J., O’bryant, S., James, I., ... & Masters, C. L. (2017). A blood-based biomarker panel indicates IL-10 and IL-12/23p40 are jointly associated as predictors of β-amyloid load in an AD cohort. Scientific Reports, 7(1), 14057. https://www.ncbi.nlm.nih.gov/pubmed/29070909

  3. Sharma, N., & Singh, A. N. (2016). Exploring biomarkers for Alzheimer’s disease. Journal of clinical and diagnostic research: JCDR, 10(7), KE01. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020308/

  4. Wang, T., Xiao, S., Liu, Y., Lin, Z., Su, N., Li, X., ... & Fang, Y. (2014). The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. International journal of geriatric psychiatry, 29(7), 713-719. https://www.ncbi.nlm.nih.gov/pubmed/24318929